Psychopharmacology
The Committee
on Psychopharmacology is GAP’s newest committee. The
Committee was established at the request of the Executive
Committee, and had its inaugural meeting in the fall
of 1998. The Committee is comprised of members with
a wide range of professional expertise; including psychopharmacology,
psychoanalysis, academics, private industry, private
practice and the federal government.
The
goal of the Committee is to examine issues related
to psychopharmacology from a broad-based eclectic
perspective. The initial project is a comprehensive
review of the role of omega-3-fatty acids in the treatment
of depression. The publication strategy is to focus
on journal articles and short reports. At present,
there are no plans to develop a full-length manuscript.
The committee intends to maintain a “GAP perspective”
in addressing issues pertaining to the ever-expanding
field of psychopharmacology.
|
